John Stone
Endocrinology, Diabetes & Metabolism · Dothan, ALNPI 1740236645
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $883 and has fallen 98.0% since, to $18 in 2024. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 161 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$561
- Dexcom, Inc.$401
- Abbott$295
- AbbVie$200
- Corcept Therapeutics$183
- Esperion Therapeutics, Inc.$137
- plus $762 from 23 others
What the payments were for
- Food & beverage$2,48798%
- Other$522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $561 |
| Dexcom, Inc. | 33 | $401 |
| Abbott | 24 | $295 |
| AbbVie | 10 | $200 |
| Corcept Therapeutics | 13 | $183 |
| Esperion Therapeutics, Inc. | 2 | $137 |
| Amarin Pharma, Inc. | 7 | $100 |
| Bayer | 6 | $85 |
| Sanofi-aventis U.S. LLC | 3 | $63 |
| Boehringer Ingelheim | 4 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Ipsen Biopharmaceuticals, Inc | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Shire North American Group Inc | 2 | $31 |
| Grifols USA, LLC | 2 | $28 |
| Insulet Corporation | 1 | $28 |
| Amgen(2 entities) | 2 | $28 |
| Johnson & Johnson | 2 | $27 |
| Baxter Healthcare | 1 | $26 |
| Welch Allyn | 1 | $26 |
| Lilly USA, LLC | 2 | $25 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| AstraZeneca | 1 | $15 |
| GRT US Holding, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Medtronic | 1 | $13 |
| Recordati_rare_diseases_inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,539 in reported general payments places this provider in the 30th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tresiba Flextouch U-200Insulin Degludec | 24 | $30,743 |
| JardianceEmpagliflozin | 11 | $13,593 |
| MounjaroTirzepatide | 12 | $12,609 |
| OzempicSemaglutide | 13 | $12,180 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $3,874 |
| Levothyroxine Sodium | 93 | $1,434 |
| Insulin SyringeSyringe-Needle,insulin,0.5 Ml | 11 | $680 |
| Metformin Hcl ErMetformin Hcl | 35 | $381 |
| Atorvastatin Calcium | 14 | $205 |
| Pioglitazone Hcl | 14 | $90 |
| Olmesartan Medoxomil | 11 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $60 | $13,59311 claims |
| Lilly USA, LLCMounjaro | $25 | $12,60912 claims |
| Novo NordiskOzempic | $561 | $12,18013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Dothan
- Bruce TrippeDothan$68K
- Steven WiseDothan$3K
- Brian WiethopDothan$2K
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
- Judson MenefeeFairhope$168K
- William DebellTuscaloosa$161K
- Edison GoncalvesBirmingham$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.